Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 3/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165106 | 0.89 | ROCK2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL175026 | 0.81 | GRM5 (0.59) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL8118536 | 0.78 | CHRNB2 (0.62) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL164387 | 0.77 | PARP14 (0.60) | ROCK2SCD5SCD | |
| SCHEMBL164419 | 0.77 | CPT2 (0.50) | GRM5ROCK2 | |
| SCHEMBL166687 | 0.77 | CPT2 (0.50) | GRM5ROCK2 | |
| SCHEMBL165920 | 0.76 | ROCK2 (0.48) | GRM5ROCK2SCD5 | |
| SCHEMBL167401 | 0.76 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL165005 | 0.75 | SCD (0.55) | ROCK2SCD5SCD | |
| SCHEMBL21535910 | 0.74 | RAB9A (0.56) | SCD5SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | CHRNB2 382/4885CHRNB4 1434/4885CHRNA3 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.